➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
McKesson
McKinsey
Baxter
Merck

Last Updated: July 2, 2020

DrugPatentWatch Database Preview

Patent: 9,943,537

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,943,537
Title:Antitumor agent and antitumor effect enhancer
Abstract: Provided is a novel method for treating a cancer using an FTD/TPI combination drug, which shows remarkably excellent antitumor effect and small adverse effects. An antitumor agent, in which a combination drug containing trifluridine and tipiracil hydrochloride at a molar ratio of 1:0.5 and an anti-VEGF antibody or anti-EGFR antibody are administered in combination.
Inventor(s): Okabe; Hiroyuki (Hanno, JP)
Assignee: TAIHO PHARMACEUTICAL CO., LTD. (Chiyoda-ku, JP)
Application Number:14/916,878
Patent Claims:see list of patent claims

Details for Patent 9,943,537

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27   Start Trial TAIHO PHARMACEUTICAL CO., LTD. (Chiyoda-ku, JP) 2033-09-06 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27   Start Trial TAIHO PHARMACEUTICAL CO., LTD. (Chiyoda-ku, JP) 2033-09-06 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Start Trial TAIHO PHARMACEUTICAL CO., LTD. (Chiyoda-ku, JP) 2033-09-06 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial TAIHO PHARMACEUTICAL CO., LTD. (Chiyoda-ku, JP) 2033-09-06 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial TAIHO PHARMACEUTICAL CO., LTD. (Chiyoda-ku, JP) 2033-09-06 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial TAIHO PHARMACEUTICAL CO., LTD. (Chiyoda-ku, JP) 2033-09-06 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 9,943,537

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Mallinckrodt
Medtronic
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.